Expertise in
7
conditions

Dr. David R. Erb

Pulmonary Medicine | Intensive Care Medicine
151 Harold Fleming Court, 
Spartanburg, SC 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Expertise in
7
conditions
151 Harold Fleming Court, 
Spartanburg, SC 
OverviewInsuranceLocationsClinical Research

Overview

David Erb is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Spartanburg, South Carolina. Dr. Erb is highly rated in 7 conditions, according to our data. His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, Lung Nodules, Pneumonia, and Advanced Bronchoscopy. Dr. Erb is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pulmonary Medicine
Intensive Care Medicine
Licenses
Critical Care Medicine in SC
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Blue Cross Blue Shield
  •  Humana

Locations

151 Harold Fleming Court, Spartanburg, SC 29303

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
Enrollment Status: Recruiting
Publish Date: February 19, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
Enrollment Status: Completed
Publish Date: December 11, 2024
Intervention Type: Biological, Drug
Study Drug: Mepolizumab
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab
Study Phase: Phase 2/Phase 3
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: October 16, 2023
Intervention Type: Drug
Study Drug: Ensifentrine
Study Phase: Phase 3
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
Enrollment Status: Completed
Publish Date: July 18, 2023
Intervention Type: Drug
Study Drugs: Gepotidacin, Nitrofurantoin
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
Enrollment Status: Completed
Publish Date: July 01, 2022
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab, LY3853113 Anti-COVID-19 Antibody, VIR-7831 Anti-COVID-19 Antibody
Study Phase: Phase 2
A Phase IV, 12 Week, Randomised, Double-blind, Double-dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI), With Tiotropium Monotherapy Based on Lung Function and Symptoms in Participants With Chronic Obstructive Pulmonary Disease
A Phase IV, 12 Week, Randomised, Double-blind, Double-dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI), With Tiotropium Monotherapy Based on Lung Function and Symptoms in Participants With Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: July 15, 2021
Intervention Type: Drug, Device
Study Phase: Phase 4
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
Enrollment Status: Completed
Publish Date: February 15, 2021
Intervention Type: Other
View 7 Less Clinical Trials

1 Total Publications

Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD.
Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD.
Journal: NPJ primary care respiratory medicine
Published: September 10, 2020
Similar Doctors
Expertise in
23
conditions
Dr. Joseph A. Boscia
Pulmonary Medicine | Intensive Care Medicine
Expertise in
23
conditions
Dr. Joseph A. Boscia
Pulmonary Medicine | Intensive Care Medicine

Upstate Lung And Critical Care Specialists PC

151 Harold Fleming Ct, 
Spartanburg, SC 
864-573-6320
Languages Spoken:
English, Castilian, Spanish
See accepted insurances
Accepting New Patients

Joseph Boscia is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Spartanburg, South Carolina. Dr. Boscia is highly rated in 23 conditions, according to our data. His top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Lung Nodules, Asbestosis, and Advanced Bronchoscopy. Dr. Boscia is currently accepting new patients.

Expertise in
17
conditions
Dr. Rico V. Mendoza
Intensive Care Medicine | Pulmonary Medicine | Sleep Medicine
Expertise in
17
conditions
Dr. Rico V. Mendoza
Intensive Care Medicine | Pulmonary Medicine | Sleep Medicine
2030 N Church St Pl, 
Spartanburg, SC 
 (1.1 mi)
864-582-5858
Languages Spoken:
English, Castilian, Filipino, Spanish
See accepted insurances
Accepting New Patients

Rico Mendoza is an Intensive Care Medicine specialist and a Pulmonary Medicine provider in Spartanburg, South Carolina. Dr. Mendoza is highly rated in 17 conditions, according to our data. His top areas of expertise are Bronchiolitis Obliterans, Industrial Bronchitis, Asthma, Advanced Bronchoscopy, and Gastrostomy. Dr. Mendoza is currently accepting new patients.

Expertise in
46
conditions
Dr. Abhijit A. Raval
Pulmonary Medicine | Hospital Medicine | Intensive Care Medicine
Expertise in
46
conditions
Dr. Abhijit A. Raval
Pulmonary Medicine | Hospital Medicine | Intensive Care Medicine

Anmed Health

2000 E Greenville St, Suite 1100, 
Anderson, SC 
 (49.7 mi)
864-225-5667
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Abhijit Raval is a Pulmonary Medicine specialist and a Hospital Medicine provider in Anderson, South Carolina. Dr. Raval is highly rated in 46 conditions, according to our data. His top areas of expertise are Pneumonia, Lung Nodules, Emphysema, Gastrostomy, and Endoscopy. Dr. Raval is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile